Abstract: A test board includes a socket, a mounting test circuit, and a relay. An analog core embedded application processor is installed into the socket. The mounting test circuit has a same configuration as an environment where the analog core embedded application processor is actually used. The relay disconnects the mounting test circuit from the socket in response to a first control signal when a vector test is performed on the analog core embedded application processor, and that connects the mounting test circuit to the socket in response to a second control signal when a mounting set test is performed on the analog core embedded application processor.

Abstract: A test board includes a socket, a mounting test circuit, and a relay. An analog core embedded application processor is installed into the socket. The mounting test circuit has a same configuration as an environment where the analog core embedded application processor is actually used. The relay disconnects the mounting test circuit from the socket in response to a first control signal when a vector test is performed on the analog core embedded application processor, and that connects the mounting test circuit to the socket in response to a second control signal when a mounting set test is performed on the analog core embedded application processor.

Abstract: The present invention relates to a vaccine prepared from an attenuated Pseudomonas aeruginosa strains which are obtained by isolating Pseudomonas aeruginosa in a pure state according to the Fisher-Devlin immunotype and then repeatedly purifying the isolated strain, particularly CFCPA 10142 (KCCM 10029), CFCPA 20215 (KCCM 10030), CFCPA 30720 (KCCM 10031), CFCPA 40057 (KCCM 10032), CFCPA 50243 (KCCM 10033), CFCPA 60534 (KCCM 10034) and CFCPA 70018 (KCCM 10035) strains. In addition, the present invention relates to a process for preparing the vaccine for immunization against Pseudomonas aeruginosa infection which contains cell wall proteins having molecular weights ranging from 10,000 to 100,000. The cell wall protein component of the attenuated strain is non-pathogenic and safe, and exhibits excellent antibody formation capacity and is useful for preparation of a vaccine and therapeutic agent.